CL King initiated coverage on Avanos Medical with a new price target
$AVNS
Industrial Specialties
Health Care
CL King initiated coverage of Avanos Medical with a rating of Buy and set a new price target of $31.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/25/2023 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 5/22/2023 | $31.00 | Buy | CL King |
| 2/24/2022 | $47.00 → $41.00 | Overweight | Keybanc |
| 1/7/2022 | $37.00 → $36.00 | Underweight | Morgan Stanley |
| 8/4/2021 | $45.00 → $41.00 | Underweight | Morgan Stanley |
| 8/4/2021 | $60.00 → $45.00 | Overweight → Equal-Weight | Stephens |
| 8/4/2021 | $55.00 → $47.00 | Overweight | Keybanc |
ALPHARETTA, Ga., Sept. 15, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS), a leading medical technology company, today announced the acquisition of Nexus Medical, LLC, a privately held medical device company based in Lenexa, Kansas. Nexus is the maker of the proprietary TKO® anti-reflux needleless connector technology, designed to support safer, more consistent nutrition and medication delivery in high-acuity settings, including Neonatal and Pediatric Intensive Care Units (NICUs and PICUs). The acquisition adds complementary technology to Avanos' Specialty Nutrition Sys
ALPHARETTA, Ga., Aug. 5, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS), a leading medical technology company, today announced the appointment of Scott Galovan as its new senior vice president, chief financial officer, effective Aug. 1, 2025. Galovan most recently served as Avanos' senior vice president of strategy and corporate development. His background with the company spans 12 years and is highlighted by a proven track record of leading a number of acquisition and divestiture initiatives. Prior to Avanos, he spent 10 years in a variety of strategy, finance, and M&A
ALPHARETTA, Ga., Aug. 5, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported second quarter 2025 financial results. "Building off our first quarter results, we delivered a strong second quarter anchored by continued healthy performance in our life-sustaining Specialty Nutrition Systems segment along with continued progress in our opioid-sparing Pain Management & Recovery segment," said David Pacitti, Avanos' chief executive officer. Pacitti continued, "Our overall execution this quarter was solid, and the steady progress we've made against each of our transfor
4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)
3 - AVANOS MEDICAL, INC. (0001606498) (Issuer)
4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)
4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)
4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)
KeyBanc Capital Markets downgraded Avanos Medical from Overweight to Sector Weight
CL King initiated coverage of Avanos Medical with a rating of Buy and set a new price target of $31.00
Keybanc reiterated coverage of Avanos Medical with a rating of Overweight and set a new price target of $41.00 from $47.00 previously
8-K - AVANOS MEDICAL, INC. (0001606498) (Filer)
10-Q - AVANOS MEDICAL, INC. (0001606498) (Filer)
8-K - AVANOS MEDICAL, INC. (0001606498) (Filer)
ALPHARETTA, Ga., Aug. 5, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS), a leading medical technology company, today announced the appointment of Scott Galovan as its new senior vice president, chief financial officer, effective Aug. 1, 2025. Galovan most recently served as Avanos' senior vice president of strategy and corporate development. His background with the company spans 12 years and is highlighted by a proven track record of leading a number of acquisition and divestiture initiatives. Prior to Avanos, he spent 10 years in a variety of strategy, finance, and M&A
ALPHARETTA, Ga., June 9, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) a leading medical technology company focused on delivered innovative healthcare solutions, today announced the appointment of Camille Chang Gilmore as senior vice president and chief human resources officer. In this role, Gilmore will lead all aspects of Avanos' people strategy, including talent acquisition and development, workforce planning, leadership development and employee experience. Her arrival reflects the company's continued commitment to building a workplace where every employee feels val
ALPHARETTA, Ga., March 17, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS), a leading medical technology company, today announced the appointment of David Pacitti as its new chief executive officer, effective April 14, 2025. Pacitti joins Avanos with a distinguished career in the healthcare sector, most recently serving as president of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers. In this capacity, he played a pivotal role in driving strategic growth and operational excellence while leading the marketing, sales, service, and support
SC 13G - AVANOS MEDICAL, INC. (0001606498) (Subject)
SC 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)
SC 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)
ALPHARETTA, Ga., Sept. 15, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS), a leading medical technology company, today announced the acquisition of Nexus Medical, LLC, a privately held medical device company based in Lenexa, Kansas. Nexus is the maker of the proprietary TKO® anti-reflux needleless connector technology, designed to support safer, more consistent nutrition and medication delivery in high-acuity settings, including Neonatal and Pediatric Intensive Care Units (NICUs and PICUs). The acquisition adds complementary technology to Avanos' Specialty Nutrition Sys
ALPHARETTA, Ga., Aug. 5, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported second quarter 2025 financial results. "Building off our first quarter results, we delivered a strong second quarter anchored by continued healthy performance in our life-sustaining Specialty Nutrition Systems segment along with continued progress in our opioid-sparing Pain Management & Recovery segment," said David Pacitti, Avanos' chief executive officer. Pacitti continued, "Our overall execution this quarter was solid, and the steady progress we've made against each of our transfor
ALPHARETTA, Ga., May 6, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported first quarter 2025 financial results. "In my first couple of weeks at Avanos, I've noticed that the transformation efforts made around the portfolio, the organizational structure and cost management have positioned us well to accelerate our growth profile," said David Pacitti, Avanos's recently appointed Chief Executive Officer. Pacitti continued, "I really like the energy and strategic focus we have right now, which can be leveraged for more consistent execution, to identify more go-t